Novocure's long-term data results of its Phase 3 EF-14 trial involving Optune combined with temozolomide are consistent with the results from the interim analysis of the data. Read More »
Celgene Corp. has purchased Triphase Accelerator Corp.'s assets regarding its proteasome inhibitor, marizomib, which is being developed for the treatment of glioblastoma and relapsed and/or refractory multiple myeloma. Read More »
Merck KGaA's businesses in Massachusetts have been ranked among the “Top Places to Work” by The Boston Globe. Read More »
Amgen's addition of RepathaA (evolocumab) to optimized statin therapy has resulted in a noteworthy statistical decrease of atherosclerosis in patients who have coronary artery disease. Read More »
Alnylam Pharmaceuticals published results from its Phase 1 clinical trial involving inclisiran in The New England Journal of Medicine. Read More »
Bristol-Myers Squibb and Innate Pharma have released the interim effectiveness analysis of its Phase 1/2 trial involving the lirilumab and Opdivo combination. Read More »
Crescendo Biosciences gave four poster presentations showcasing Vectra DA at the American College of Rheumatology meeting in Washington D.C. this week. Read More »
The American Cancer Society has partnered with the CVS Health Foundation to present grants to 20 institutions across the United States for their Tobacco-Free Generation Campus Initiative. Read More »
Janssen-Cilag International NV's STELARA has been approved by the European Commission to treat adult patients who have moderate-to-severe Crohn’s disease and did not respond well to or are immune to conventional therapy or a tumor necrosis factor alpha antagonist. Read More »
Biothera Pharmaceuticals recently presented new Phase 2 Imprime PGG preclinical data that will corroborate the drug’s ability to produce coordinated innate and adaptive immune responses that could increase the effectiveness of other checkpoint inhibitor therapies. Read More »
Imprimis Pharmaceuticals has reached a purchase and supply agreement with the specialty pharmacy division of one of the country’s biggest pharmacy benefits managers Read More »
Amgen plans to partner with Janssen Biotech to further assess the drug combination of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen. Read More »
Vemlidy, Gilead Sciences’s treatment for chronic hepatitis B virus with compensated liver disease, has been approved by the U,S. Food and Drug Administration. Read More »
The Prostate Cancer Foundation has revealed its new corporate identity, which includes the tagline “Curing Together.” Read More »
Prime Therapeutics has released a report detailing the rising cost of autoimmune drugs. Read More »
Janssen Pharmaceuticals Inc.'s results of its XARELTO Phase 3b PIONEER AF-PCI clinical trial and new research involving INVOKANA will be featured in presentations at the American Heart Association Scientific Sessions, being held through Wednesday in New Orleans. Read More »
Mallinckrodt Pharmaceuticals' OFIRMEV injection has received a Prior Approval Supplement from the U.S. Food and Drug Administration. Read More »
Walgreens Boots Alliance Inc. was recently honored by the American Ireland Fund at the 32nd Annual Chicago Dinner by awarding it with the American Ireland Fund Corporate Social Responsibility Award. Read More »
Innovus Pharmaceuticals and Elis Pharmaceuticals have finalized a second exclusive license and distribution agreement for Zestra. Read More »
Roche's VENTANA ALK (D5F3) CDx Assay has received approval from the U.S. Food and Drug Administration to be used in conjunction with the VENTANA BenchMark ULTRA automated slide stainer. Read More »
Alerts Sign-up
